Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Other Accumulated Expenses: 2022-2023

Historic Other Accumulated Expenses for Immunocore Holdings (IMCR) over the last 2 years, with Dec 2023 value amounting to $6.0 million.

  • Immunocore Holdings' Other Accumulated Expenses was N/A to $7.5 million in Q1 2024 from the same period last year, while for Mar 2024 it was $7.5 million, marking a year-over-year change of. This contributed to the annual value of $6.0 million for FY2023, which is 62.74% up from last year.
  • Latest data reveals that Immunocore Holdings reported Other Accumulated Expenses of $6.0 million as of FY2023, which was up 62.74% from $3.7 million recorded in FY2022.
  • Over the past 5 years, Immunocore Holdings' Other Accumulated Expenses peaked at $6.0 million during FY2023, and registered a low of $3.7 million during FY2022.
  • Moreover, its 2-year median value for Other Accumulated Expenses was $4.8 million (2022), whereas its average is $4.8 million.
  • Data for Immunocore Holdings' Other Accumulated Expenses shows a peak YoY surged of 62.74% (in 2023) over the last 5 years.
  • Over the past 2 years, Immunocore Holdings' Other Accumulated Expenses (Yearly) stood at $3.7 million in 2022, then soared by 62.74% to $6.0 million in 2023.